

Legend for supplementary

Supplementary Table 1a: Demographic data for the 12 patients for which microarray data are shown in table 2.

Supplementary Table 1b: Demographic data for the 25 patients for which flow cytometry data are shown in table 3a.

Supplementary Table 1c: Characteristics of 37 patients for which flow cytometry data are shown in table 3b and table 4a and 4b.

Supplementary Figure 1: Gating strategy and representative biomarkers in the study.

Supplementary Figure 2: Box plot illustrates the % of EOMES+Ki67+CD8+ T cells in normal donors, relapsed and NED melanoma patients in the trial. Whiskers in box plots indicate maximum and minimum values measured. Cross indicates the mean, while line indicates the median. P-values in the graph are from Wilcoxon rank-sum test. Overall p-value=0.038 for comparing the three groups from Kruskal-Wallis test.

Supplementary Table 1a. Patient Demographics for the Microarray cohort (n=12)


Variable	Level	n (%)
gender	F	4 (33.3)
	M	8 (66.7)
stage	III	4 (33.3)
	IV	8 (66.7)
HLA A2	A2+	7 (58.3)
	A2-	5 (41.7)
dosage	10 mg/kg	12 (100)
	3 mg/kg	0 (0)
irAE	N	7 (58.3)
	Y	5 (41.7)
Outcome	NED	12 (100)
	Relapse	0 (0)

Supplementary Table 1b. Demographics of patients with 3-month measurements (n=25)


Variable	Level	n (%)
gender	F	9 (36.0)
	M	16 (64.0)
stage	III	10 (40.0)
	IV	15 (60.0)
HLA A2	A2+	18 (72.0)
	A2-	7 (28.0)
dosage	10 mg/kg	16 (64.0)
	3 mg/kg	9 (36.0)
irAE	N	15 (60.0)
	Y	10 (40.0)
Outcome	NED	17 (68.0)
	Relapse	8 (32.0)

Supplementary Table 1c. Demographics of patients with 6-month measurements (n=37)

Variable	Level	n (%)
gender	F	12 (32.4)
	M	25 (67.6)
stage	III	17 (45.9)
	IV	20 (54.1)
HLA A2	A2+	20 (54.1)
	A2-	17 (45.9)
dosage	10 mg/kg	31 (83.8)
	3 mg/kg	6 (16.2)
irAE	N	23 (62.2)
	Y	14 (37.8)
Outcome	NED	27 (73.0)
	Relapse	10 (27.0)



Supplementary figure 1



Supplementary figure 2